Study to Assess Adverse Events and the Movement of Oral Venetoclax Tablet Through the Body of Female Participants Aged 18-75 Years With Impaired Renal Function
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trials Related to Venetoclax
Related studies linked through entity extraction aliases.
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)
- Status
- TERMINATED
- Phase
- PHASE1
Lymph Node Microenvironment Modifications in Patients With CLL Treated With Venetoclax-based Regimens
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE4
Study of Magrolimab Combinations in Participants With Myeloid Malignancies
- Status
- TERMINATED
- Phase
- PHASE2
Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated
- Status
- TERMINATED
- Phase
- PHASE3
Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL)
- Status
- RECRUITING
- Phase
- PHASE2
A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05)
- Status
- TERMINATED
- Phase
- PHASE1
Clinical Study With Ibrutinib and Venetoclax for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
A Safety, Tolerability and Preliminary Efficacy Study of CC-90011 in Combination With Venetoclax and Azacitidine in R/R Acute Myeloid Leukemia and Treatment-naïve Participants Not Eligible for Intensive Therapy
- Status
- TERMINATED
- Phase
- PHASE1
Venetoclax and ASTX727 for the Treatment of Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
A Dose-Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Follicular Lymphoma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
- Status
- RECRUITING
- Phase
- PHASE2/PHASE3
Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years Old
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
- Status
- TERMINATED
- Phase
- PHASE2
Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2